Daiichi Sankyo

News

ESMO: Trodelvy's overall survival benefit revealed

Prospects for Gilead Sciences' Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury i

News

Enhertu role in breast cancer confirmed, as Daiichi wins Sea...

AstraZeneca and Daiichi Sankyo have the confirmatory trial data they were hoping for with Enhertu as a treatment for advanced, HER2-positive breast cancer in previously-treated patients.

Oncology

New horizons in breast cancer care

Interview with Markus Kosch, Daiichi Sankyo head of Oncology Business Division in Europe.

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ and Daiichi's TROP2 ADC shows promise in first-line lung ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanc

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

FDA verdict on Enhertu in HER2-low breast cancer due before ...

AstraZeneca and Daiichi Sankyo will hear back from the FDA before the end of 2022 on their license application for Enhertu in HER2-low breast cancer – an indication which could drive the dr

News

Court won't raise Seagen damages award in Enhertu patent dis...

A Texas court has confirmed the $41.8 million damages awarded to Seagen in its patent dispute with Daiichi Sankyo over beast cancer drug Enhertu, but declined to raise the sum despite concl

ESMO: Trodelvy's overall survival benefit revealed

Enhertu role in breast cancer confirmed, as Daiichi wins Sea...

New horizons in breast cancer care

AZ and Daiichi's TROP2 ADC shows promise in first-line lung ...

FDA verdict on Enhertu in HER2-low breast cancer due before ...

Court won't raise Seagen damages award in Enhertu patent dis...

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Daiichi Sankyo

Editor's Picks